Zai Lab Ltd.
- ZLAB ยท Nasdaq
- Pharmaceutical Preparations
- Shanghai, China
- 1,784 employees
- CIK 0001704292
Updated from SEC filings through
Top things to know
Executives
- Ying Du Chairperson & CEO Form 4, July 6, 2026
- Yajing Chen Chief Financial Officer Form 4, August 21, 2026
- Frazor Titus Edmondson III Chief Legal Officer Form 4, June 29, 2026
- Yizhe Wang Operating Partner Form 4, June 8, 2026
- F. Ty Edmondson Chief Legal Officer and Corporate Secretary DEF 14A, April 28, 2026
- Rafael G. Amado President, Head of Global Research and Development DEF 14A, April 28, 2026
What leadership is saying
“We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
Zai Lab Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Shanghai, China. It trades as ZLAB on Nasdaq. Revenue was $460M in the fiscal year ending December 31, 2025, +15.3% from the year before. It reported about 1,784 employees. Ying Du is Chairperson & CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $460M 10-K, 2026-02-26 | $399M 10-K, 2026-02-26 | $267M 10-K, 2026-02-26 | $215M 10-K, 2025-02-27 | $144M 10-K, 2024-02-27 |
| Operating income | -$229M 10-K, 2026-02-26 | -$282M 10-K, 2026-02-26 | -$367M 10-K, 2026-02-26 | -$404M 10-K, 2025-02-27 | -$700M 10-K, 2024-02-27 |
| SG&A | $278M 10-K, 2026-02-26 | $299M 10-K, 2026-02-26 | $282M 10-K, 2026-02-26 | $259M 10-K, 2025-02-27 | $219M 10-K, 2024-02-27 |
| Net income | -$176M 10-K, 2026-02-26 | -$257M 10-K, 2026-02-26 | -$335M 10-K, 2026-02-26 | -$443M 10-K, 2025-02-27 | -$704M 10-K, 2024-02-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Ying Du | Chairperson & CEO | Form 4, July 6, 2026 |
| Samantha (Ying) Du | Board member (per proxy) bio: Founder, Chairperson of the Board of Directors, and Chief Executive Officer | DEF 14A, April 28, 2026 |
| Yajing Chen | Chief Financial Officer | Form 4, August 21, 2026 |
| Frazor Titus Edmondson III | Chief Legal Officer | Form 4, June 29, 2026 |
| F. Ty Edmondson | Named in proxy bio: Chief Legal Officer and Corporate Secretary | DEF 14A, April 28, 2026 |
| Rafael G. Amado | Named in proxy bio: President, Head of Global Research and Development | DEF 14A, April 28, 2026 |
| Yizhe Wang | Operating Partner | Form 4, June 8, 2026 |
| John David Diekman | Board member (per proxy) bio: Lead Independent Director | DEF 14A, April 28, 2026 |
| Nisa Bernice Wing-Yu Leung | Board member (per proxy) bio: Independent Director | DEF 14A, April 28, 2026 |
| Richard Brian Gaynor | Board member (per proxy) bio: Independent Director | DEF 14A, April 28, 2026 |
What Zai Lab Ltd does
We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 88.6 million (as of February 26, 2021) | 10-K, March 1, 2021 |
|---|---|---|
| Public float | $3.8B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting June 17, 2026 (filed April 28, 2026) | DEF 14A, April 28, 2026 |
| Auditor | Kpmg LLP (Short Hills, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 10, 2026 | Richard Gaynor Director | Buy | 1,228 | $33K | Form 4, November 13, 2026 |
| August 19, 2026 | Yajing Chen Chief Financial Officer | Sale | 260 | $7K | Form 4, August 21, 2026 |
| August 12, 2026 | William Lis Director | Sale | 8,506 | $213K | Form 4, August 13, 2026 |
| August 11, 2026 | Yajing Chen Chief Financial Officer | Sale | 619 | $15K | Form 4, August 13, 2026 |
| July 1, 2026 | Richard Gaynor Director | Buy | 1,736 | $33K | Form 4, July 6, 2026 |
| June 30, 2026 | Ying Du Chairperson & CEO | Sale | 7,026 | $130K | Form 4, July 1, 2026 |
| June 26, 2026 | Frazor Titus Edmondson III Chief Legal Officer | Sale | 4,103 | $72K | Form 4, June 29, 2026 |
| June 26, 2026 | Ying Du Chairperson & CEO | Sale | 24,543 | $429K | Form 4, June 29, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-23
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-17
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-21
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-10-16
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2025-08-07
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Zai Lab Ltd
- What does Zai Lab Ltd do?
- In its own words, from Item 1 of its 10-K: "We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health."
- What is Zai Lab Ltd's revenue?
- $460M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Zai Lab Ltd profitable?
- Zai Lab Ltd reported net income of -$176M for the fiscal year ending December 31, 2025.
- How many employees does Zai Lab Ltd have?
- About 1,784 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Zai Lab Ltd?
- Ying Du, Chairperson & CEO, as named in a 4 filed July 6, 2026.
- Who is the CFO of Zai Lab Ltd?
- Yajing Chen, Chief Financial Officer, as named in a 4 filed August 21, 2026.
- Where is Zai Lab Ltd headquartered?
- Shanghai, China.
- What is Zai Lab Ltd's stock ticker?
- ZLAB on Nasdaq.
- What industry is Zai Lab Ltd in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Zai Lab Ltd's website?
- zailaboratory.com.
- When does Zai Lab Ltd report earnings next?
- February 4, 2027. Source: estimate_8k_pattern.
- Is Zai Lab Ltd a public company?
- Yes. Zai Lab Ltd files with the SEC under CIK 0001704292 and trades as ZLAB.
- Who audits Zai Lab Ltd?
- Kpmg LLP, Short Hills, New Jersey, as named in its latest annual report (10-K).
- How many shares of Zai Lab Ltd are outstanding?
- 88.6 million shares as of February 26, 2021, from its 10-K filed March 1, 2021.
- What is Zai Lab Ltd's public float?
- $3.8B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Zai Lab Ltd report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is Zai Lab Ltd's annual shareholder meeting?
- June 17, 2026, per its proxy statement (DEF 14A) filed April 28, 2026.
- Have Zai Lab Ltd insiders traded stock recently?
- Since June 30, 2025, officers and directors reported 44 open-market sales worth about $19.1M and 4 purchases worth about $388K on Forms 4 and 5. The most recent: Richard Gaynor (Director) bought 1,228 shares on November 10, 2026.